Post-axial limb defects with maternal sodium valproate exposure

Area of Science:

• Medical Genetics
• Teratology
• Pediatric Orthopedics

Background:

• Valproate (VPA) is a widely used antiepileptic and mood-stabilizing drug.
• Maternal VPA use during pregnancy is associated with an increased risk of congenital malformations.
• Specific VPA-associated birth defects include neural tube defects and facial clefts.

Observation:

• A male infant presented with bilateral talipes equinovarus (clubfoot).
• The infant also exhibited absent fibulae, tibial bowing, and shortening.
• Facial dysmorphic features were noted in the affected child.

Findings:

• The infant's mother reported daily use of 2000 mg sodium valproate for seizure control during pregnancy.
• This case suggests a potential association between intrauterine VPA exposure and postaxial limb defects.
• The observed limb malformations align with patterns seen in valproate embryopathy.

Implications:

• Highlights the need for careful risk-benefit assessment of valproate use in pregnant women.
• Suggests further research into the teratogenic mechanisms of valproate on limb development.
• Emphasizes the importance of prenatal counseling regarding potential fetal risks associated with maternal antiepileptic drug use.